{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T12:21:12Z","timestamp":1777724472075,"version":"3.51.4"},"reference-count":49,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2024,3,4]],"date-time":"2024-03-04T00:00:00Z","timestamp":1709510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Investigative Medicine"],"published-print":{"date-parts":[[2024,4]]},"abstract":"<jats:p>HMG-CoA reductase inhibitors (statins) are commonly used to manage dyslipidemia to reduce cardiovascular disease (CVD) risk. High-sensitivity C-reactive protein (hs-CRP) is an emerging systematic low-grade inflammatory marker associated with atherosclerotic CVD development. Despite racial\/ethnic disparities in the use and response of statins and the anti-inflammatory effects of statins, the effectiveness of statins on inflammation and metabolic markers is unknown among Hispanics. We performed a retrospective cohort study using 150 adult patients scheduled for an annual physical examination at a family medicine clinic between January 1, 2021 and December 31, 2021. Effect size with a 95% confidence interval (CI) was estimated using adjusted regression analyses. Among 150 patients, 52 (34.7%) patients received statins. Patients who received statins had significantly reduced median hs-CRP (1.9 vs 3.2, p\u2009=\u20090.007), mean low-density lipoprotein (LDL-C; 101.2 vs 124.6, p\u2009&lt;\u20090.001), and total cholesterol (172.6 vs 194.5, p\u2009&lt;\u20090.001) concentrations compared to those who did not receive statins. In the propensity-scores matched analysis, lower concentrations of log-transformed hs-CRP (regression coefficient (RC), \u22120.48; 95% CI: \u22120.89, \u22120.07), LDL-C (RC, \u221219.57; 95% CI: \u221233.04, \u22126.10), and total cholesterol (RC, \u221223.47; 95% CI: \u221238.96, \u22127.98) were associated with statin use. In addition, hepatic steatosis (adjusted relative risk (aRR)\u2009=\u20090.25; 95% CI: 0.08, 0.78, p\u2009=\u20090.017) was significantly lower among patients with the use of statins. Our study suggests that HMG-CoA reductase inhibitors may help reduce inflammation among Hispanic patients with dyslipidemia and hypertension. These findings have useful implications for preventing risk and disparities associated with cardiovascular and other inflammatory-induced diseases among the fastest-growing US Hispanic minorities.<\/jats:p>","DOI":"10.1177\/10815589241234962","type":"journal-article","created":{"date-parts":[[2024,2,18]],"date-time":"2024-02-18T23:02:20Z","timestamp":1708297340000},"page":"359-369","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Effectiveness of HMG-CoA reductase inhibitors on inflammation and metabolic markers in the US-Mexico border Hispanic population"],"prefix":"10.1177","volume":"72","author":[{"given":"Phong","family":"Nguyen","sequence":"first","affiliation":[{"name":"Paul L. Foster School of Medicine, Texas Tech University Health Sciences Center El Paso, El Paso, TX, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vishwajeet","family":"Singh","sequence":"additional","affiliation":[{"name":"Biostatistics and Epidemiology Consulting Lab, Texas Tech University Health Sciences Center El Paso, El Paso, TX, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vikram","family":"Thakur","sequence":"additional","affiliation":[{"name":"Department of Molecular and Translational Medicine, Texas Tech University Health Sciences Center El Paso, El Paso, TX, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alok Kumar","family":"Dwivedi","sequence":"additional","affiliation":[{"name":"Paul L. Foster School of Medicine, Texas Tech University Health Sciences Center El Paso, El Paso, TX, USA"},{"name":"Biostatistics and Epidemiology Consulting Lab, Texas Tech University Health Sciences Center El Paso, El Paso, TX, USA"},{"name":"Department of Molecular and Translational Medicine, Texas Tech University Health Sciences Center El Paso, El Paso, TX, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Munmun","family":"Chattopadhyay","sequence":"additional","affiliation":[{"name":"Paul L. Foster School of Medicine, Texas Tech University Health Sciences Center El Paso, El Paso, TX, USA"},{"name":"Department of Molecular and Translational Medicine, Texas Tech University Health Sciences Center El Paso, El Paso, TX, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2024,3,4]]},"reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10557-008-6113-z"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.13044"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1582-4934.2001.tb00172.x"},{"key":"e_1_3_2_5_2","unstructured":"Linton MF Yancey PG Davies SS et al. The role of lipids and lipoproteins in atherosclerosis. In: Feingold KR Anawalt B Blackman MR et al. (eds.) Endotext [Internet]. South Dartmouth (MA): MDText.com Inc.; 2000."},{"issue":"9","key":"e_1_3_2_6_2","first-page":"e18273","article-title":"The effect of statin therapy on inflammatory biomarkers: a systematic review","volume":"13","author":"Proute MC","year":"2021","unstructured":"Proute MC, Kothur N, Georgiou P, et al. The effect of statin therapy on inflammatory biomarkers: a systematic review. Cureus 2021; 13(9): e18273.","journal-title":"Cureus"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa042378"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.5114\/aoms.2020.100304"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2013.07.113"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvp249"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2006.01.059"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2005.10.070"},{"issue":"2","key":"e_1_3_2_13_2","first-page":"225","article-title":"Caracteristiques immunoanalytiques de la proteine C-reactive et de la proteine C-reactive ultrasensible [Immunoanalytical characteristics of C-reactive protein and high sensitivity C-reactive protein]","volume":"75","author":"Moutachakkir M","year":"2017","unstructured":"Moutachakkir M, Lamrani Hanchi A, Baraou A, et al. Caracteristiques immunoanalytiques de la proteine C-reactive et de la proteine C-reactive ultrasensible [Immunoanalytical characteristics of C-reactive protein and high sensitivity C-reactive protein]. Ann Biol Clin (Paris) 2017; 75(2): 225\u2013229.","journal-title":"Ann Biol Clin (Paris)"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.619564"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1002\/ptr.7262"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.880298"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32511-3"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.14943"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.2174\/1381612825666190117114305"},{"key":"e_1_3_2_20_2","first-page":"1564","volume-title":"J Am Coll Cardiol","volume":"77","author":"Nurmohamed NS","year":"2021","unstructured":"Nurmohamed NS, Navar AM, Kastelein JJP. New and emerging therapies for reduction of LDL-cholesterol and apolipoprotein B: JACC focus seminar 1\/4. J Am Coll Cardiol2021; 77(12): 1564\u20131575."},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1003121"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.115.002905"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.5551\/jat.RV16004"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2014.07.026"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1080\/02664763.2013.840772"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1136\/jim-2022-002479"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1002\/cnr2.1211"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.4103\/0971-5916.166582"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa032804"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdiacomp.2011.10.001"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2019.00103"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-019-1433-3"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0807646"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)60367-5"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/8732360"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-139-8-200310210-00011"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.21037\/apm-21-1243"},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.3390\/healthcare8040361"},{"key":"e_1_3_2_39_2","doi-asserted-by":"publisher","DOI":"10.7326\/M23-0720"},{"key":"e_1_3_2_40_2","doi-asserted-by":"publisher","DOI":"10.1136\/jim-2022-002487"},{"key":"e_1_3_2_41_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11906-022-01167-8"},{"key":"e_1_3_2_42_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2006.04.014"},{"key":"e_1_3_2_43_2","doi-asserted-by":"publisher","DOI":"10.1136\/bjsports-2017-098497"},{"key":"e_1_3_2_44_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2009.01.053"},{"key":"e_1_3_2_45_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.36.0917"},{"key":"e_1_3_2_46_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.44.6831"},{"issue":"9","key":"e_1_3_2_47_2","first-page":"e10446","article-title":"Pleiotropic effects of statins in the light of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis","volume":"12","author":"Ahsan F","year":"2020","unstructured":"Ahsan F, Oliveri F, Goud HK, et al. Pleiotropic effects of statins in the light of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Cureus 2020; 12(9): e10446.","journal-title":"Cureus"},{"key":"e_1_3_2_48_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2010.12.017"},{"key":"e_1_3_2_49_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.ATV.0000160548.78317.29"},{"key":"e_1_3_2_50_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2016.11.073"}],"container-title":["Journal of Investigative Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10815589241234962","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10815589241234962","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10815589241234962","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T10:40:01Z","timestamp":1777459201000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10815589241234962"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,4]]},"references-count":49,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["10.1177\/10815589241234962"],"URL":"https:\/\/doi.org\/10.1177\/10815589241234962","relation":{},"ISSN":["1081-5589","1708-8267"],"issn-type":[{"value":"1081-5589","type":"print"},{"value":"1708-8267","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,4]]}}}